Somatics LLC

Psychiatrists Dismiss Patient Evidence Against ECT as “Anecdotal” to Protect Profits

by

In 2015, the U.S. Food and Drug Administration issued its “Neurological Devices; Reclassification of Electroconvulsive Therapy Devices Intended for Use in Treating,” recommending that the ECT device be rated Class II (less risk classification than its current Class III) for: Severe major depressive episode (MDE) associated with major depressive disorder (MDD) or bipolar disorder (BPD) … Read more

Conflicts of Interest Regarding ECT Covers Up Damage

by

Excerpted from CCHR’s submission to the FDA opposing its 2015 proposal to reclassify the ECT device as a Class II low risk device. CCHR’s submission was submitted in March 2016. The Food and Drug Administration (FDA) Proposal in 2015 to reduce the risk classification of the ECT device instead of banning it, is of enormous … Read more